JP Morgan Chase’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

JP Morgan Chase’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-618,089	Closed	-$28.7M	–	7858
2023 Q2	$28.7M	Buy	618,089 +571,732	+1,233%	+$19.8M	﹤0.01%	1439
2023 Q1	$1.33M	Buy	46,357 +8,775	+23%	+$260K	﹤0.01%	3836
2022 Q4	$1.17M	Buy	37,582 +12,728	+51%	+$415K	﹤0.01%	3937
2022 Q3	$504K	Buy	24,854 +4,864	+24%	+$88.6K	﹤0.01%	4460
2022 Q2	$311K	Buy	19,990 +9,901	+98%	+$170K	﹤0.01%	4837
2022 Q1	$193K	Buy	10,089 +1,567	+18%	+$28K	﹤0.01%	5212
2021 Q4	$215K	Buy	+8,522	New	+$250K	﹤0.01%	5308

JP Morgan Chase's DICE Position: Q3 2023 in Review

JP Morgan Chase sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 618,089 shares — an estimated $28.7M sold.

JP Morgan Chase first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $28.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

JP Morgan Chase reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 618,089 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $28.7M.
JP Morgan Chase first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
JP Morgan Chase's DICE Therapeutics, Inc. Common Stock position peaked at $28.7M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.